GDUFA II Negotiations: Let the Saber-Rattling Begin
This article was originally published in RPM Report
The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.
You may also be interested in...
Amid a storm of controversy about “re-pricing” of older brands, the US Congress has reacted in two seemingly contradictory ways. First, new legislation creates what amounts to a tax on generic drug companies who raise prices. At the same time, legislators are eager to press FDA to move faster on generic drug approvals to assure competition for high priced brands.
FDA is ready to restore some informal communications for generic drugs, but only for applications not covered by the newly implemented user fee action dates.
Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.